BeLiver at ESMO Molecular Analysis for Precision Oncology Congress 2025

🔬 Predictive oncology in the spotlight at ESMO #MAP2025.

💡 Our CSO, Frederic Saltel, and Deputy CTO, Hadrien Mary, were at the conference to present our work on predicting treatment response in advanced liver cancer. With first-line therapies failing in up to 70% of cases, oncologists urgently need better tools. Our research shows how proteomic signatures can provide the biological rationale that is currently missing.

🚀 At BeLiver, we are committed to translating this science into a clinical reality to improve patient survival and quality of life. Our goal is simple: to give every patient the best chance of success, right from the first treatment.